To include your compound in the COVID-19 Resource Center, submit it here.

Replagal agalsidase alfa: Approved in Europe; under FDA review

TKTX said that in 15 females with Fabry disease, Replagal had similar

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE